Wednesday, July 8, 2026
🇺🇸 FDA

pharma · HIV-1 Infection · HIV-1 infection

Gilead Sciences

Gilead Sciences Pty Limited

Gilead Sciences clinical programs — 30 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
333 Lakeside Drive, Foster City, CA 94404, US HQ
1987 Founded
14,602 Employees
TGA registrant Type
Company details
Status
Public
HQ
333 Lakeside Drive, Foster City, CA 94404, US
Founded
1987
Employees
14,602
Programs
30
Drugs
54
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Gilead Sciences projects

30 ClinicalTrials.gov programs sponsored by Gilead Sciences.

Gilead Sciences has 30 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

30 programs

Clinical programs

  1. CB8025-31731-RE

    Gilead Sciences Pty Limited

    Primary Biliary Cholangitis

    phase 3 other active

    1 trial

  2. GS-5245 tablets 175 mg, GS-5245 tablets 350 mg

    Gilead Sciences Pty Limited

    COVID-19

    phase 3 small molecule active

    1 trial

  3. GS-US-174-0144

    Gilead Sciences Pty Limited

    Hepatitis B Infection

    phase 3 small molecule active

    1 trial

  4. GS-US-528-6727

    Gilead Sciences Pty Limited

    Human Immunodeficiency Virus (HIV-1) infection

    phase 3 small molecule active

    1 trial

  5. GS-US-563-5925

    Gilead Sciences Pty Limited

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  6. GS-US-563-5926

    Gilead Sciences Pty Limited

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  7. GS-US-577-6153

    Gilead Sciences Pty Limited

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  8. GS-US-592-6173

    Gilead Sciences Pty Limited

    PD-L1 Positive Metastatic Triple-Negative Breast Cancer

    phase 3 small molecule active

    1 trial

  9. GS-US-592-6238

    Gilead Sciences Pty Limited

    PD-L1-negative metastatic triple-negative breast cancer or PD-L1-positive metastatic triple-negative breast cancer previously treated with an anti-PD-(L)1 agent in the curative setting

    phase 3 small molecule active

    1 trial

  10. GS-US-595-6184

    Gilead Sciences Pty Limited

    Triple Negative Breast Cancer

    phase 3 small molecule active

    1 trial

  11. GS-US-600-6165

    Gilead Sciences Pty Limited

    Extensive Stage Small Cell Lung Cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  12. GS-US-621-6290

    Gilead Sciences Pty Limited

    HIV-1 infection

    phase 3 small molecule active

    1 trial

  13. GS-US-621-6463

    Gilead Sciences Pty Limited

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  14. GS-US-626-6216

    Gilead Sciences Pty Limited

    Metastatic Non–Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  15. GS-US-682-6769

    Gilead Sciences Pty Limited

    Recurrent or Persistent Endometrial Cancer

    phase 3 small molecule active

    1 trial

  16. GS-US-695-6509

    Gilead Sciences Pty Limited

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  17. GS-US-695-7156

    Gilead Sciences Pty Limited

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  18. IMMU-132-13

    Gilead Sciences Pty Limited

    Locally Advanced or Metastatic Unresectable Urothelial Cancer

    phase 3 small molecule active

    1 trial

  19. Placebo to match 10 mg, Placebo to match 5 mg

    Gilead Sciences Pty Limited

    Primary Biliary Cholangitis

    phase 3 small molecule active

    1 trial

  20. EDGE-Lung

    Gilead Sciences Pty Limited

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  21. GS-4321 PLACEBO

    Gilead Sciences Pty Limited

    Chronic Hepatitis Delta.

    phase 2 small molecule active

    1 trial

  22. GS-US-409-5704

    Gilead Sciences Pty Limited

    Ulcerative Colitis (UC)

    phase 2 small molecule active

    1 trial

  23. GS-US-576-6220

    Gilead Sciences Pty Limited

    Non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  24. GS-US-699-7184-01

    Gilead Sciences Pty Limited

    Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  25. IMMU-132-06

    Gilead Sciences Pty Limited

    Locally Advanced/Metastatic Urothelial Cancer

    phase 2 small molecule active

    1 trial

  26. Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  27. GS-5245 tablets 175 mg, GS-5245 tablets 350 mg

    Gilead Sciences Pty Limited

    Renal Impairment

    phase 1 small molecule active

    1 trial

  28. Study of GS-0151 in Participants With Rheumatoid Arthritis

    Gilead Sciences Pty Limited

    Rheumatoid Arthritis

    phase 1 other active

    1 trial

  29. Study of GS-5319 in Adults With Solid Tumors

    Gilead Sciences Pty Limited

    Advanced solid tumors

    phase 1 other active

    1 trial

  30. Biktarvy 50 mg/200 mg/25 mg film-coated tablets

    Gilead Sciences Pty Limited

    HIV-1 infection

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Gilead Sciences have?

30 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.